Forbes has recognized Adele on its Midas List of top 100 technology investors worldwide, top 10 life science investors and top women in venture capital.

Adele Oliva brings decades of finance and healthcare experience to 1315 Capital, including approximately 20 years in private equity. Throughout her investing career, she has focused on commercial stage specialty pharmaceutical, medical technology, and healthcare service investments.

Adele co-founded 1315 Capital in 2015 to establish a firm focused on healthcare growth investing. She was recruited to Quaker Partners in 2007 to expand their growth and expansion stage investing practice. Prior to Quaker, Adele was Co-Head of US Healthcare at Apax Partners, a global private equity firm, where she started in 1997.

Adele has served on the board of many high growth companies including Ascent Healthcare Solutions (acquired by Stryker), EKR Therapeutics (acquired by Cornerstone Therapeutics), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Precision Dermatology (acquired by Valeant), Prometheus Labs (acquired by Nestle) and SkinMedica (acquired by Allergan). She currently serves on the boards of Innovative Health, NovaSom, Onkos Surgical, and TELA Bio.

Prior to entering private equity as a Kauffman Fellow, Adele built a strong foundation in finance and healthcare at CoreStates in commercial banking and Baxter Healthcare in marketing and business development.

Adele received a BS from St. Joseph’s University and an MBA from Cornell University, where she was awarded the Albert Fried Fellowship.